<DOC>
	<DOCNO>NCT02322957</DOCNO>
	<brief_summary>This study design evaluate potential PK drug-drug interaction FV-100 ritonavir . The study single-center , open-label , randomize , 2-way crossover design healthy volunteer .</brief_summary>
	<brief_title>A Study Investigating Pharmacokinetics FV-100 With Without Ritonavir Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Capable give write informed consent Nontobacco user least 3 month prior selection Healthy basis physical examination , medical history , ECG clinical laboratory test screening ( must NOT meet follow ) Infected Hepatitis A , B , C , HIV History current medical condition could impact safety participant A positive urine drug test Consumption 2 unit alcoholic beverage per day 14 per week Received investigational drug vaccine use investigational medical device within 3 month 5 halflives plan start treatment prior treatment FV100 Subjects use drug substance know inhibit induce cytochrome ( CYP ) P450 enzymes and/or Pgp within 28 day prior first dose throughout study Subjects , within 2 week prior first dose study drug , ingest grapefruit grapefruit juice , apple orange juice , vegetables mustard green family charbroiled meat</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>